Production (Stage)
Barinthus Biotherapeutics plc
BRNS
$0.654
-$0.156-19.26%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 14.97M | 14.97M | 14.97M | 0.00 | 334.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 14.97M | 14.97M | 14.97M | 0.00 | 334.00K |
| Cost of Revenue | 8.92M | 11.70M | 12.25M | 11.11M | 11.63M |
| Gross Profit | 6.05M | 3.27M | 2.72M | -11.11M | -11.29M |
| SG&A Expenses | 30.60M | 24.01M | 41.02M | 28.42M | 34.35M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -1.00M | -976.00K | -792.00K | -582.00K | -5.00K |
| Total Operating Expenses | 64.98M | 60.90M | 77.70M | 68.72M | 77.24M |
| Operating Income | -50.01M | -45.93M | -62.73M | -68.72M | -76.91M |
| Income Before Tax | -65.35M | -61.23M | -58.75M | -65.33M | -73.34M |
| Income Tax Expenses | -29.00K | -44.00K | -867.00K | -1.47M | -2.60M |
| Earnings from Continuing Operations | -65.32 | -61.18 | -57.88 | -63.86 | -70.74 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 88.00K | 109.00K | 55.00K | 78.00K | 88.00K |
| Net Income | -65.23M | -61.07M | -57.83M | -63.79M | -70.66M |
| EBIT | -50.01M | -45.93M | -62.73M | -68.72M | -76.91M |
| EBITDA | -46.80M | -43.33M | -60.12M | -66.12M | -74.47M |
| EPS Basic | -1.64 | -1.55 | -1.49 | -1.65 | -1.83 |
| Normalized Basic EPS | -0.74 | -0.69 | -0.95 | -1.06 | -1.19 |
| EPS Diluted | -1.65 | -1.56 | -1.49 | -1.65 | -1.84 |
| Normalized Diluted EPS | -0.74 | -0.69 | -0.95 | -1.06 | -1.19 |
| Average Basic Shares Outstanding | 158.88M | 157.39M | 155.82M | 154.93M | 154.30M |
| Average Diluted Shares Outstanding | 158.88M | 157.39M | 155.82M | 154.93M | 154.30M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |